Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ

Authors: Shu-Chuan Chang, Sheng-Shun Yang, Chiu-Chun Chang, Chun-Che Lin, Yueh-Chin Chung, Tsai-Chung Li

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

Interferon (IFN) therapy can cause significant side effects in chronic hepatitis C (CHC) patients; however, the health-related quality of life (HRQOL) of antiviral-treated CHC patients has not been established in Taiwan. This study evaluated domains and the degree to which antiviral treatment affects the HRQOL in CHC patients and identifies factors associated with variations between patients.

Methods

Health-related quality of life (HRQOL) was assessed using the Short Form-36 (SF-36) and the Chronic Liver Disease Questionnaire (CLDQ) in 108 antiviral-treated CHC patients. Eight scales and two summary scales of the SF-36 were compared with 256 age- and gender-matched population norms and 64 age- and gender-matched CHC patients without antiviral therapy. Descriptive statistic measures, one-way ANOVA, and regression analysis were used for data analysis.

Results

(1) CHC patients receiving antiviral treatment displayed significantly lower scores in six scales, the Physical Component Summary (PCS), and the Mental Component Summary (MCS) of the SF-36, when compared to the population norms and patients without antiviral therapy (p < 0.05). (2) The mean CLDQ score of antiviral-treated patients was lower than that of patients without antiviral therapy, including subscales of ‘fatigue’, ‘systemic symptoms’, and ‘role emotion’. (3) All SF-36 subscales significantly correlated with all CLDQ subscales, with the greatest correlation coefficients shown between fatigue and vitality and mental health of SF-36. (4) Antiviral therapy had a greater negative impact on females in the CLDQ, on all patients during treatment weeks 9–16 in the PCS and on patients with a monthly income of less than NT$10,000 in the CLDQ, PCS, and MCS.

Conclusions

This study highlighted impairments in the quality of life of chronic hepatitis C patients treated with IFN-based therapy. The significant factors associated with HRQOL include gender, income, and treatment duration. The results of this study might provide nurses with a comprehensive understanding of HRQOL and its determining factors in antiviral-treated CHC patients. The findings can serve as a useful reference for nursing personnel in developing instructions for upgrading the care of CHC patients.
Literature
1.
go back to reference Chen C, Yang P, Huang G, Lee H, Sung J, Sheu J: Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007, 106(2):148–155.CrossRefPubMed Chen C, Yang P, Huang G, Lee H, Sung J, Sheu J: Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007, 106(2):148–155.CrossRefPubMed
3.
go back to reference Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C: Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8(11):924.CrossRefPubMed Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C: Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8(11):924.CrossRefPubMed
5.
go back to reference Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975–982.CrossRefPubMed Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975–982.CrossRefPubMed
6.
go back to reference Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958–965.CrossRefPubMed Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958–965.CrossRefPubMed
7.
go back to reference Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5):S237-S244.CrossRefPubMed Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5):S237-S244.CrossRefPubMed
8.
go back to reference Liu C, Liu C, Lin C, Liang C, Hsu S, Yang S, Hsu C, Tseng T, Wang C, Lai M, Chen J, Chen P, Chen D, Kao J: Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47(10):1260–1269.CrossRefPubMed Liu C, Liu C, Lin C, Liang C, Hsu S, Yang S, Hsu C, Tseng T, Wang C, Lai M, Chen J, Chen P, Chen D, Kao J: Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47(10):1260–1269.CrossRefPubMed
9.
go back to reference Kinder M: The lived experience of treatment for hepatitis C. Gastroenterol Nurs 2009, 32(6):401–408.CrossRefPubMed Kinder M: The lived experience of treatment for hepatitis C. Gastroenterol Nurs 2009, 32(6):401–408.CrossRefPubMed
10.
go back to reference Liu J, Lin C, Hu S, Liang M, Zhao Z, Gao Z: Quality of life in patients with chronic hepatitis C after PEG-Interferon a-2a therapy. Zhonghua Gan Zang Bing Za Zhi 2011, 19(12):890–893.PubMed Liu J, Lin C, Hu S, Liang M, Zhao Z, Gao Z: Quality of life in patients with chronic hepatitis C after PEG-Interferon a-2a therapy. Zhonghua Gan Zang Bing Za Zhi 2011, 19(12):890–893.PubMed
11.
go back to reference Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang J, Melin P, Cacoub P: Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011, 31(4):516–524.CrossRefPubMed Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang J, Melin P, Cacoub P: Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011, 31(4):516–524.CrossRefPubMed
12.
go back to reference Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45(2):295–300.PubMedCentralCrossRefPubMed Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45(2):295–300.PubMedCentralCrossRefPubMed
13.
go back to reference Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu M, Ware JE Jr: A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7(1):39–55.CrossRefPubMed Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu M, Ware JE Jr: A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7(1):39–55.CrossRefPubMed
14.
go back to reference Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS: Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007, 65(7):227–234.PubMed Gutteling JJ, de Man RA, Busschbach JJ, Darlington AS: Overview of research on health-related quality of life in patients with chronic liver disease. Neth J Med 2007, 65(7):227–234.PubMed
15.
go back to reference Arora S, O’Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J: Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006, 21(2):406–412.CrossRefPubMed Arora S, O’Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J: Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006, 21(2):406–412.CrossRefPubMed
16.
go back to reference Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky J, Neumann AU, Schalm SW, de Knegt RJ: Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol 2012, 12: 11–11.PubMedCentralCrossRefPubMed Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky J, Neumann AU, Schalm SW, de Knegt RJ: Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol 2012, 12: 11–11.PubMedCentralCrossRefPubMed
17.
go back to reference Martin LM, Sheridan MJ, Younossi ZM: The impact of liver disease on health-related quality of life: a review of the literature. Curr Gastroenterol Rep 2002, 4(1):79–83.CrossRefPubMed Martin LM, Sheridan MJ, Younossi ZM: The impact of liver disease on health-related quality of life: a review of the literature. Curr Gastroenterol Rep 2002, 4(1):79–83.CrossRefPubMed
18.
go back to reference Steel JL, Chopra K, Olek MC, Carr BI: Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res 2007, 16(2):203–215.CrossRefPubMed Steel JL, Chopra K, Olek MC, Carr BI: Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res 2007, 16(2):203–215.CrossRefPubMed
19.
go back to reference Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G: Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001, 96(7):2199–2205.CrossRefPubMed Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G: Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001, 96(7):2199–2205.CrossRefPubMed
20.
go back to reference Younossi Z, Kallman J, Kincaid J: The effects of HCV infection and management on health-related quality of life. Hepatology 2007, 45(3):806–816.CrossRefPubMed Younossi Z, Kallman J, Kincaid J: The effects of HCV infection and management on health-related quality of life. Hepatology 2007, 45(3):806–816.CrossRefPubMed
21.
go back to reference Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, Mohamed MK: Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004, 40(6):1434–1441.PubMedCentralCrossRefPubMed Schwarzinger M, Dewedar S, Rekacewicz C, Abd Elaziz KM, Fontanet A, Carrat F, Mohamed MK: Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology 2004, 40(6):1434–1441.PubMedCentralCrossRefPubMed
22.
go back to reference Björnsson E, Verbaan H, Oksanen A, Frydén A, Johansson J, Friberg S, Dalgård O, Kalaitzakis E: Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol 2009, 44(7):878–887.CrossRefPubMed Björnsson E, Verbaan H, Oksanen A, Frydén A, Johansson J, Friberg S, Dalgård O, Kalaitzakis E: Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scand J Gastroenterol 2009, 44(7):878–887.CrossRefPubMed
23.
go back to reference Kwan JW, Cronkite RC, Yiu A, Goldstein MK, Kazis L, Cheung RC: The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res 2008, 17(5):715–724.CrossRefPubMed Kwan JW, Cronkite RC, Yiu A, Goldstein MK, Kazis L, Cheung RC: The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Qual Life Res 2008, 17(5):715–724.CrossRefPubMed
24.
go back to reference Chang S, Ko W, Wu S, Peng C, Yang S: Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J Formos Med Assoc 2008, 107(6):454–462.CrossRefPubMed Chang S, Ko W, Wu S, Peng C, Yang S: Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. J Formos Med Assoc 2008, 107(6):454–462.CrossRefPubMed
25.
go back to reference Huang L, Sung H, Liu L, Chang T: Distress, Depression and Quality of Life in Patients With Chronic Hepatitis C Treated With interferon and Ribavirin. J Nurs Healthc Res 2010, 6(3):183–190. Huang L, Sung H, Liu L, Chang T: Distress, Depression and Quality of Life in Patients With Chronic Hepatitis C Treated With interferon and Ribavirin. J Nurs Healthc Res 2010, 6(3):183–190.
26.
go back to reference Ware JE: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston: Health Assessment Lab: New England Medical Center; 1994. Ware JE: SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston: Health Assessment Lab: New England Medical Center; 1994.
27.
go back to reference Lu JR, Tseng HM, Tsai YJ: Assessment of health-related quality of life in Taiwan (I): development and psychometric testing of SF-36 Taiwan version. Taiwan J Public Health 2003, 22: 501–511. Lu JR, Tseng HM, Tsai YJ: Assessment of health-related quality of life in Taiwan (I): development and psychometric testing of SF-36 Taiwan version. Taiwan J Public Health 2003, 22: 501–511.
28.
go back to reference Tseng HM, Lu JR, Tsai YJ: Assessment of health-related quality of life in Taiwan (II): norming and validation of SF-36 Taiwan version. Taiwan J Public Health 2003, 22: 512–518. Tseng HM, Lu JR, Tsai YJ: Assessment of health-related quality of life in Taiwan (II): norming and validation of SF-36 Taiwan version. Taiwan J Public Health 2003, 22: 512–518.
29.
go back to reference Li TC, Lin CC, Lee YD: Validation of the Chinese (Taiwan) version of SF-36 health survey in a random sample of central Taiwan population. Quality Life Research 2000, 9(9):1060. Li TC, Lin CC, Lee YD: Validation of the Chinese (Taiwan) version of SF-36 health survey in a random sample of central Taiwan population. Quality Life Research 2000, 9(9):1060.
30.
go back to reference Chang S, Chen T, Pai L, Yang S, Huang J: Factors Associated with the Quality of Life of Patients with Chronic Liver Disease. Chang Gung Nursing 2011, 22(3):321–333. Chang S, Chen T, Pai L, Yang S, Huang J: Factors Associated with the Quality of Life of Patients with Chronic Liver Disease. Chang Gung Nursing 2011, 22(3):321–333.
31.
go back to reference Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473–483.CrossRefPubMed Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473–483.CrossRefPubMed
32.
go back to reference McHutchison JG, Ware JEJ, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34(1):140–147.CrossRefPubMed McHutchison JG, Ware JEJ, Bayliss MS, Pianko S, Albrecht JK, Cort S, Yang I, Neary MP: The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001, 34(1):140–147.CrossRefPubMed
33.
go back to reference Miller ER, Hiller JE, Shaw DR: Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001, 25(4):355–361.CrossRefPubMed Miller ER, Hiller JE, Shaw DR: Quality of life in HCV-infection: lack of association with ALT levels. Aust N Z J Public Health 2001, 25(4):355–361.CrossRefPubMed
34.
go back to reference Spiegel BMR, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41(4):790–800.CrossRefPubMed Spiegel BMR, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F: Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41(4):790–800.CrossRefPubMed
35.
go back to reference Kang S, Hwang S, Lee S, Chang F, Lee S: Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005, 11(47):7494–7498.CrossRefPubMed Kang S, Hwang S, Lee S, Chang F, Lee S: Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol 2005, 11(47):7494–7498.CrossRefPubMed
36.
go back to reference Hollander A, Foster GR, Weiland O: Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006, 41(5):577–585.CrossRefPubMed Hollander A, Foster GR, Weiland O: Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006, 41(5):577–585.CrossRefPubMed
37.
go back to reference Asadi Noghabi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH: The Effect of Education on Quality of Life in Patients under Interferon Therapy. Hepat Mon 2010, 10(3):218–222.PubMedCentralPubMed Asadi Noghabi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH: The Effect of Education on Quality of Life in Patients under Interferon Therapy. Hepat Mon 2010, 10(3):218–222.PubMedCentralPubMed
38.
go back to reference Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001, 96(2):579–583.CrossRefPubMed Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001, 96(2):579–583.CrossRefPubMed
39.
go back to reference Foster GR: Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009, 16(9):605–611.CrossRefPubMed Foster GR: Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009, 16(9):605–611.CrossRefPubMed
40.
41.
go back to reference Lam ETP, Lam CLK, Lai CL, Yuen MF, Fong DYT, So TMK: Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes 2009, 7: 52–52.PubMedCentralCrossRefPubMed Lam ETP, Lam CLK, Lai CL, Yuen MF, Fong DYT, So TMK: Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes 2009, 7: 52–52.PubMedCentralCrossRefPubMed
42.
go back to reference Schulz K, Kroencke S, Ewers H, Schulz H, Younossi ZM: The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res 2008, 17(4):575–584.CrossRefPubMed Schulz K, Kroencke S, Ewers H, Schulz H, Younossi ZM: The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). Qual Life Res 2008, 17(4):575–584.CrossRefPubMed
43.
go back to reference Hauser W, Schnur M, Steder-Neukamm U, Muthny FA, Grandt D: Validation of the German version of the Chronic Liver Disease Questionnaire. Eur J Gastroenterol Hepatol 2004, 16(6):599–606.CrossRefPubMed Hauser W, Schnur M, Steder-Neukamm U, Muthny FA, Grandt D: Validation of the German version of the Chronic Liver Disease Questionnaire. Eur J Gastroenterol Hepatol 2004, 16(6):599–606.CrossRefPubMed
44.
go back to reference Ferrer M, Córdoba J, Garin O, Olivé G, Flavià M, Vargas V, Esteban R, Alonso J: Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl 2006, 12(1):95–104.CrossRefPubMed Ferrer M, Córdoba J, Garin O, Olivé G, Flavià M, Vargas V, Esteban R, Alonso J: Validity of the Spanish version of the Chronic Liver Disease Questionnaire (CLDQ) as a standard outcome for quality of life assessment. Liver Transpl 2006, 12(1):95–104.CrossRefPubMed
Metadata
Title
Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
Authors
Shu-Chuan Chang
Sheng-Shun Yang
Chiu-Chun Chang
Chun-Che Lin
Yueh-Chin Chung
Tsai-Chung Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-12-97

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue